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                                                           INTRODUCTION
Pain is one of the commonest and most unpleasant symptom that leads the patient to 
seek medical advice and whatever may be the cause it demands relief. Pain is a sensation which 
produces a reaction consisting of withdrawal response  ,metabolic response, hormonal response 
and conscious aversion.
Pain  has  been  defined  by  IASP  [International  association  for  study  of  pain]  as  an 
unpleasant sensory and emotional experience associated with actual or potential tissue damage 
or described in terms of such damage .The relief of post-operative pain is a  subject which has 
been receiving an increasing amount of attention in the past few years
Pain relief is necessary for 1.Humanitarian and 2. Therapeutic reasons. Pain relief must 
be 1.Effective 2.Safe 3.feasible Post operative pain relief is important in reducing the morbidity 
after surgery .Pain causes peripheral vasoconstriction, reduces functional residual capacity and 
sputum clearance.
Post  operative  pain  relief  has  the  following  advantages-it  can  reduce  the  metabolic 
response to trauma, thus may prevent negative nitrogen balance. Moreover the pain relieved 
patient  has  better  mobility  with  reduced  incidence  of  chest  infections  and   deep  vein 
thrombosis. Patients with Hypertension and ischemic heart disease, when allowed to experience 
pain in the post operative period may develop a reactionary rise in blood pressure,tachycardia 
and may go for subendocardial ischemia, infarction, hence the need for post operative pain 
relief 1,2.
Spinal  anaesthesia  continues  to  be  one  of  the  commonest   regional  anaesthetic 
techniques because of rapid onset, safety and simplicity. The use of neuraxial additive drugs 
with  local  anaesthetic  agents  has  proved  to  exert  synergistic  action  hence  the  various 
combinations have been tried.
Studies on tissue compatibility (eg ) CSF indicate that buprenorphine and Midazolam 
may safely be adminsiterd epidurally and intrathecally.  The use of neuraxial additive drugs 
have shown that  this  method of Pain relief provide prolonged segmental  analgesia without 
systemic side effects of narcotics or the sensory, motor or autonomic block seen  with regional 
anaesthetic techniques for pain relief3.
Since  many orthopaedic operations are performed frequently under sub arachnoid block it was 
decided to assess and compare the post-operative  analgesia and side effects of buprenorphine and 
midazolam co-administered separately with subarachnoid anaesthetic agents like bupivacaine where 
longer duration of pain relief is required.
AIM OF THE STUDY
To  evaluate  the  Post  –operative  analgesic  effects  of  Intrathecal  Bupivacaine  with 
Buprenorphine  and  Intrathecal  Bupivacaine  with  Midazolam  following  orthopaedic 
surgeries(lower limbs).
The parameters that were analysed are
1. Duration of analgesia
2. Quality and adequacy of analgesia as per the visual analog scale
3. Effects of Drugs on Cardio-Respiratory and Central Nervous System
4. Undesirable  side  effects  like  Motor  Weakness,  Urinary  retention,  nausea  and 
vomiting, Neurological dysfunction and allergic reaction(like pruritus)
METHODS OF POST-OPERATIVE PAIN RELIEF
Post –operative pain  is an acute pain which starts with the surgical trauma and usually 
ends with tissue healing.
Techniques of Post -operative Analgesia
Peri operative pain is divided in to three phases4
1. Intra-operative pain
2. Early post –operative pain: this is  a sharp acute pain requiring potent analgesia and 
lasts for 1-4 days by which time endogenous opioid secretion takes place .
3. Late Post-operative pain-This is a dull continuous pain. 
The various modalities available for post –operative pain relief  are
I. Opiates
i. Intramuscular
ii. Continuous/intermittent intravenous
iii. Patient  controlled Analgesia(PCA)
iv. Intrathecal/Epidural
v. Others
II. Non- Narcotic 
Invasive
 i Local Anaesthtic infiltration
ii. Regional Anaesthesia
iii. Cryoanalgesia
iv. Continuous  intrapleural  infusion
III. Non –Invasive:
i. Inhalational
ii. Transcutaneous electrical nerve stimulation
iii. Hypnosis
iv. Electro –Acupuncture
v. Relaxational techniques.
Any technique to be efficient must start before the onset of pain and continue throughout 
the duration of pain.
I. Opiates
Opiates have remained the cornerstone for management of moderate and severe  pain.
i. Intramuscular Opiates
 The  Commonest   mode  of  administration  remains  intermittent,  intramuscular 
administration  with the  interval  up to  8  hours.  This  results  in  oscillation  of  plasma levels 
between  supra-analgesic  peaks  associated  with  toxic  effects  and   sub-analgesic   troughs 
associated with pain.
Agents Bolus Dose (mg) Receptor Duration (Hr)
Morphine 10 Mu 3.4
Pethidine 100 Mu 3
Buprenorphine 0.3 Mu 8
Fentanyl 0.1 Mu 1-2
Pentazocine 30-60 Sigma <3
ii. Continuous / Intermittent  Intravenous 
Mathers and Cousins described the concept of Minimum effective concentration(MEC) of an 
analgesic in blood based on Pharmacokinetics. Loading dose of the analgesic =(VDSSxMEC) mg. It 
is infused over 15-16 mts
Maintenance infusion=(clearancexMEC)mg/hr.
iii. Patient controlled Analgesia(PCA)
In 1971 Sechzer described the demand analgesia concept in which the patient is given 
small increments of morphine on demand. This had high degree of patient satisfaction and 
significantly low total drug usage.
A simple device is Cardiff Palliator and one demand analgesia computer.  Overdosage 
and respiratory depression will be less likely with PCA.
iv. Spinal/ Epidural opioids:- 
 The Potency of analgesia by these routes results from action of the opioid on inhibitory 
dorsal horn opioid receptors5.
DOSAGE SCEHDULES FOR SPINAL(EPIDURAL OPIOIDS)
Drug Epidural
Dose (mg)
Intrathecal
Dose (mg)
Duration
(Hrs)
Side effects Respirator
y
Depression
Comment
Morphine 1-10 0.1-0.5 12-24 itching, 
nausea, 
vomiting, 
micturition 
difficulties
Yes Slow  onset 
delayed 
respiratory 
depression
Pethidine 50-100 10-30 3-6 Itching, 
nausea, 
vomiting and 
sedation
Yes Marked 
sedation
Fentanyl 0.025-0.01
5
0.02-0.1 2-8 Itching, 
nausea and 
vomiting
Slight
Buprenorphine 0.06-0.3 19 Itching, 
nausea and 
vomiting
Rare
Side effects of spinal/epidural opioids
Side Effects Treatment
a. Common 1.Nausea and vomiting Antiemetics
2.Pruritus Metoclopramide
3.Urinary retention Antihistamines
4.Sedation Cathetrisation
b.Rare and serious Respiratory depression Ventliation
c.Less common Neurological risks 
arachnoiditis
Naloxone Doxapram
v. Other Routes of administration of opiates
Oral: MST is a continuous sustained release preparation of morphine.If gastric motility 
is present. It gives analgesia for up to 24 hrs comparable to i.m administration but absorption is 
erratic and side effects  troublesome. OTEC (oral transmucosal fentanyl citrate) is available  as 
a lollipop candy. 
Sublingual:  Buprenorphine  02-0.4  mg in  the  form of  tablet  is  highly  effective  and 
convenient. But it has ceiling effect on analgesia and it has slow onset(three hours) of action.
Transdermal: Analgesia  with fentanyl patch100-200 mcg lasts upto two hours.
Rectal: MHS (Morphine hypogel suppository) is useful in paediatric patients but has 
very erratic absorption.
II.Non-Narcotic Techniques
A.Invasive Techniques:
a. Continuous   Epidural  Adminstration  of  Local  Anaesthetics Repeated  doses  or 
continuous infusion or even PCA administration of local  anaesthetic can be used for post-
operative analgesia.
Advantage: Profound  analgesia with no respiratory depression.
Disadvantages:  Tachyphylaxis,  toxic  effects  of  local  anaesthetic  drugs  catheter 
migration  causing  total  spinal  block,  symphathetic   blockade  causing  hypotension  and 
contraindication in patients on anticoagulants.
b. Continuous  Intrathecal  Infusion:  Continuous  infusion  of  local  anaesthetics  via  32 
S.W.G. Catheter introduced through a No.29LP needle has been described but the prohibitive 
costs as well as technical difficulties should be quiet apparent.
c. Other Epidural Drugs: Midazolam 5 mg gives analgesia lasting 12 hours. Drowsiness 
is  reported but  becomes less significant after 2 hours. Calcitonin 100mcg with lignocaine and 
adrenaline produced good analgesia. It acts through serotoninergic pathways.
d. Local Nerve Blocks: Commonly used in   post-operative analgesia are: Intercostal nerve 
block  for  upper  abdominal  and  thoracic  surgery.Illioinguinal  andIlliohypogastric  block, 
brachial  plexus  block,  continuous  nerve  sheath  block  and  simple  incision  infiltration  with 
bupivacaine.
e. Intrapleural Infusion: It gives excellent analgesia but the large doses utilized (30mlof 
0.5% bupivacaine) result in significantly high blood levels associated with toxicity.
f. Cryoanalgesia: It is ideal for post throracotomy  and subcostal or flank incision. The 
nerve is cooled to-20degree °C  with a liquid  nitrogen probe. It causes axon destruction with 
preservation of nerve sheaths.
Advantages: Excellent  analgesia lasting for days  with no side effects.
Disadvantages:No  analgesia  to  surgical  drain  sites,  prolonged  anaesthetic  patch, 
specialized equipment required.
Non-Invasive Techniques
a.  Inhalation: Nitrous oxide inhalation can be used in post-operative ventilated patients. 
Beyond 36-48 hours it can cause bone marrow  depression.
b. Transcutaneous  Electrical  Nerve  Stimulation(TENS):An  asymmetric  biphasic 
waveform of 12-20m Amp and stimulation frequency is delivered. The electrodes are applied 
on either side of the incision and stimulation started immediately in the post-operative period.
Advantages: are low cost and no side effects. Disadvantages; are incomplete analgesia 
but it remains  a very useful adjuvant to opiates and can lower the dose required.
c. Electroacupunture: The disadvantages of this procedure are specialized equipment  and 
technical skill are required and analgesia may be inadequate.
d. Other  drugs:Non-steroidal  anti-inflammatory  drugs(NSAIDS)such   as    aspirin, 
ibuprofen are useful adjuvants in children and very useful for late post-operative pain. But they 
inhibit  gastric  cyclo-oxygenase  causing   bleeding  and  ulceration.  Decreased  platelet 
aggregation and coagulation may cause increased wound bleeding.
e. Newer Drugs:
Ketorolac  Tromethamine:  This  is  a   peripherally   acting  non  opioid,  nonsteroidal 
analgesic.It inhibits pain by inhibiting prostaglandin synthesis.
Dose:  Injection  ketorolac  30  mg (im)  6-8  hourly  (or)  Tablet  ketorolac  10-30 mg 6 
hourly.
Side effects: Nausea, vomiting , somnolence, hyperkinesia and myalgia.
Nefopam: This is a cyclised analog of diphenhydramine with a unique central action. 
Dose:  Tablet  NefoPam  (30mg)30-60mg  6  hourly  or  injectionNefopam  20  mg(im) 
4-6hourly or slow (i.v)4-6hourly
Side effects: Nausea, vomiting , drowsiness, insomnia and headache.
Ketamine:A  Phencyclidine  derivative,  which  causes   profound   analgesia  without 
respiratory depression.
Clonidine:  Alpha  2  adrenergic  agonist  used   orally  can  augment  spinally  mediated 
opioid  analgesia whereas   epidural or intrathecal clonidine can provide effective analgesia 
alone.
Intrathecal Neostigmine: Provides analgesia by inhibiting breakdown of acetylcholine, 
an endogenous spinal neurotransmitter. Analgesia and side effects are  dose dependent.
Intra-articular  Analgesia:  by  Morphine,and  intra  articular  bupivacaine  provide 
analgesia following arthroscopic and other joint surgery.
Noise: Random noise has been used to reduce pain during dental surgery. Music has 
been used in the management of post-operative  pain and   the effects probably partly due to 
distraction6,7.
ANATOMY
The bony spinal canal extends from the foramen magnum to the sacral hiatus. It is joined 
inferiorly by the border of vertebrae, laterally by pedicles and posteriorly by the laminae and 
spines.  The  only  opening  in  the  canal  are  the  intervertebral  foramina  which   permits  the 
passage of the segmental nerve and the blood vessels.
The contents of the canal are:
1. Roots of spinal nerve
2. Spinal membranes with enclosed cord and CSF.
3. Venousplexus and alveolar tissue of extradural spaces.
The Spinal Cord
The  spinal  cord  is  an  elongated  cylindrical  mass  of  nervous  tissue  4m  in  length 
occupying the upper 2/3 of vertebral canal. At its rostral end, it is continuous with medulla 
oblongata and below ends in conus medullaris, from the apex of which filum terminale interna 
descends with dura and arachnoid mater to the level of 2nd sacral vertebra. It pierces the dura 
and arachnoid and continues below as filum terminale externa, eventually blending with the 
periosteum on the back of coccyx.
Spinal nerves emerge from spinal cord in pairs.  8 cervical,  12 thoracic,  5 lumbar,  5 
sacral and one pair of coccygeal nerve. The spinal nerve composed of anterior and posterior 
roots,  each  with  the  3  meningeal  coverings  cross  the  extradural  space  and  unite  in  the 
intervertebral foramina to form the spinal nerve trunks which soon divide into anterior and 
posterior primary division and mixed nerve. These nerve roots within the duramater have no 
dural sheath and are therefore easily affected by doses of analgesic drugs brought into contact 
with them.
Vascular supply of the spinal cord
One anterior and two posterior spinal arteries on each side arise from the postero-inferior 
cerbellar artery at the base of the brain. They supply part of the posterior horn and posterior 
column of spinal cord and replenished by numerous segmental arteries, the posterior radicular 
arteries. There is only a single anterior spinal artery arising from the union of a small branch 
from each vertebral artery. The anterior and posterior spinal arteries do not anastomose with 
each other. The spinal veins form anterior and posterior plexuses, which drain into the vertebral 
azygos and lumbar veins.
Indentification of spinal verterbral level
1. The line joining the illiac crest passes through the L4 vertebra (or) L4-L5 space.
2. A line  drawn between the  joints  where  the  lateral  edge  of  the  erector  spinae 
muscles meet the lower border of the 12th rib. This line passes through the lower border of L1 
spinous process.
3. With the arm by the sides, the horizontal line joining the lower border of both 
scapulae pass usually though T7 vertebral space.
Structures pierced while performing a subarachnoid block
Skin
Subcutaneous tissue
Supraspinous ligament
Inter spinous ligament
Ligamentum flavum
Duramater
Pain Pathways
Pain receptors appear to consist of peripheral plexus of unmyelinated nerves, activated 
by high intense stimuli which may be, thermal, chemical (or) mechanical. Pain is conducted 
along two types of fibres in the periphery, `A' delta and `C' fibres. `A' delta fibres are rapidly 
conducting (12-30 metre/sec). They appear to conduct the sharp pain produced by pinprick (or) 
electrical stimuli. `C' fibres are very fine un-myelinated fibres which conduct at a very slow 
rate of 2-3 metres/sec. their threshold  for stimulation is higher than that of `A' delta fibres.
Peripheral  sensory  neurons  have their  cell  bodies  in  the  dorsal  root  ganglia  and the 
Central projections of the `A' delta and `C' fibres enter the dorsal horn in the lateral division of 
the dorsal root. `A' delta and `C' fibres terminate principally in the marginal layer (Lamina-I) 
and substantia gelatinosa (Lamina II). Some of the neurons of Lamina I synapse with `A' delta 
columns without synapsing with neurons from the deeper layers. The majority of fibres synapse 
with substantia gelatinusa and send projection to deeper layers (or) synapse with the dendrites 
of neurons whose cell bodies reside in deeper layers principally in Lamina V.
The central projections form cell bodies in  Lamina IV, V and VI with a contribution 
from Lamina I cross the midline in the anterior commissure to form spino-thalamic tract, which 
ends in the thalamus. The ventro-posterior nucleus of the thalamus projects to the post-central 
gyrus, the sensory cortex where the anatomical representation is reasonably precise. While it 
appears  that  the  thalamus  is  involved  in  the  experience  of  pain,  the  post-central  gyrus  is 
necessary  for  its  accurate  localisation  and  prefrontal  cortex  for  the  unpleasant  affective 
reactions to it.
PHYSIOLOGY
Physiology of pain
The transmission of pain has four distinct physiologic processes.
1. Transudation: Conversion of noxious stimuli into electrical signals by peripheral 
afferrents.
2. Transmission: Propagation of electrical signals along the nociceptive pathways
3. Modulation: Alteration of the nociceptive signal within the dorsal horn.
4. Perception: Nociceptive  input is integrated with cognitive and emotional factors to 
create subjective pain.
Intrathecal space
Spinal anaesthesia may be defined as the temporary interruption of transmission of nerve impulses 
produced by the injection of local anaesthetic agents into the spinal space. Sites of action of local 
anaesthetics placed in the subarachnoid space in order of importance  are 
1. Primary- on nerve roots of spinal cord.
2. Secondary –on dorsal root ganglia and postero- anterior horn synapse.
3. Limited and incomplete – in spinal cord parenchyma on ascending – descending tracts.
Direct effects of Local anaesthetics injected  into subarachnoid space:
When the nerve roots are exposed to an anaesthetic solution the blocking action is 
primaril a function of fibre size.
Susceptibility depends on
1. Fibre size
2. The degree of myelinization and the distance between the nodes of ranvier.
3. Frequency of nerve impulse transmission.
           Generally local anaesthetic agents block transmission most easily in the smaller fibre, 
such as  the thinly myelinated B  fibre carrying symphathetic impulses and the non-myelinated 
C  fibres  carrying  pin-prick  sensation.  Block  of  the  A  fibres,  the  large  motor  fibres  and 
medullated proprioceptive fibres is slow in onset and of shorter duration . They are the last to 
be blocked.
Sequence  of Nerve modality Block
Observation of a patient after spinal  block will  reveal the sequence of block of  the 
various nerve modalities as
1. Vasomotor block- dilation of skin vessels and increased cutaneous blood flow
2. Block of cold temperature fibres.
3. Sensation of warmth by patient.
4. Temperature discrimination is lost.
5. Slow pain.
6. Fast pain.
7. Tactile sense lost.
8. Motor paralysis –extensor muscles are affected before the flexor muscles
9. Pressure sense abolished
10. Proprioception is lost.
During recovery anaesthesia recedes from head and feet areas towards the midline (i.e) a point near 
the site of anaesthetic agent is the last to recover.
Opiate  receptors
Opiates produce their action through specific recognition sites (or) receptors. Opiate receptors  are 
wide spread in the brain stem and spinal cord. They are found in areas associated with the 
emotions,the amygdala and limbic system, in the area postrema associated with stimulant effect 
upon the chemoreceptor trigger zone and along the course of pain pathways in the medial thalamus, 
in the periaqueductal gray matter and in the substantia gelatinosa of trigeminal nerve, spinal cord 
and the gastro- intestinal tracts.
The possible mechanism of action of these exogenously administered opioid may be by8 
1. Stimulation of the stereo specific receptors.
2. A local anaesthetic like action on the surface of excitable cell membrane that does not 
involve a stereospecific receptor (opioid agonists)
3. Blockade of the neuron excitability by a mechanism which hyperpolarizes the cellular 
membrane  and  make  them  more  difficult  to  depolarize  and  thus  decreases  neuro-
transmission.
Classification of opiate receptors:
Martin and coworkers (1976) proposed three classes of opiate receptors based on the studies on dogs 
with morphine and some benzomorphin derivatives-M(Mu) receptors. Kappa receptors and sigma 
receptors. To this the Kosteshitz classification would add delta receptors to explain certain selective 
effects of Leu enkephalins.
Mu receptors:
The MU receptor is a major antinociceptor site located in both  the brain and spinal cord with 
highest concentration in the periaqueductal grey matter and substantia gelatinosa respectively. 
Opioid induced analgesia at the MU  receptor is dose dependent. Morphine is a typical agonist at 
this receptor. The MU receptor is thought to mediate supra analgesia, respiratory depression, 
euphoria and physical dependence.
Mu receptor have been further classified in to 
Mu1-Those with high affinity –mediate analgesia 
Mu2-Those with low affinity –not associated with analgesia.
           Respiratory depression is probably through Mu2 receptor.
Kappa receptor
Ketocyclazocine and ethyl ketocyclazocine were proposed as Kappa agonists and have a 
greater effect on spinal nociceptive responses than  supraspinal response although the kappa 
receptor agonists were associated with sedation and miosis.
Sigma receptor
Interaction with proposed sigma receptor was not associated with reduced response to noxious 
stimuli but associated with mydriasis, tachycardia and mania, subsequently these receptors have 
been associated with the pshycomimetic action of many opioid derivatives. A typical agonist  is N 
allyl norcyclazocine.  Respiratory and vasomotor stimulation were  also observed on interaction 
with this receptor.
Delta receptor
Studies  in guinea pig brain using methionine  and leucine enkephalin suggested another opioid 
receptor which is designated the delta  receptor. At this receptor stable enkephalin analogue D 
Aladien Enkephalin(DADL)has greater activity than Mu agonist drugs.
Epsilon Receptor
At this receptor electrical stimulation are blocked by beta endorphins, a stable peptide with opioid 
activity, found mainly in the pituitary.
Endorphins and Enkephalins
Endogenous opioid  activity in brain and pituitary extracts was described soon after the  discovery of 
opioid  receptor. Two pentapeptides with opioid activity were isolated from the brain and named as 
Enkephalins and are further classified into Met -enkephalin  and Leu-enkephalins. Subsequently 
other  polypeptides  were identified namely endorphins  which are of four types namely alpha, beta, 
delta and gamma endorphins. Beta endorphin is widely distributed but found principally in 
hypothalamus where it is  passed  via long axons to third ventricle after release into CSF. Beta 
endorphins can  act on opioid receptor in the brain stem and spinal cord. Beta endorphins appear to 
possess all the activity of morphine producing analgesia, euphoria, behavioural effects  and 
hypoglycemia and to be equipotent on all opioid receptors.
Sites and Mechanism of action of opioid induced analgesia:
In 1979, Wang et al  reported  remarkable pain relief using subarachnoid morphine in 
cancer  patients  with  demonstration  of  opiate  receptors  in  the  spinal  cord  and  segmental 
analgesia from intrathecal opiates in rats. Many clinical trials of their use in the treatment of 
post-operative, chronic and obstetric pain were performed.
Spinal  opiates  administration  produce  segmental  analgesia,  the  extent  and  spread  of 
which is dependent on site of injection and position, while the duration is little longer than that 
produced by bupivacaine. Yakash and Rudy showed that the potency and duration of analgesia 
of the Mu agonists- fentanyl, morphine and pethidine given intrathecally to rats corresponds to 
the systemic properties  and that  the kappa and partial  antagonists  pentazocine,  cyclazocine 
were ineffective.
In man opiates have been used successfully chiefly in the treatment of chronic pain, 
post-operative and obstetric  pain. Neither analgesia nor side effects are likely to result from 
systemic absorption of spinally  administered opioids.  Intrathecal  morphine is  effective in a 
dose well below that required for systemic effects  while analgesic effect generally correlates 
poorly with plasma concentration following epidural fentanyl, pethidine and  morphine.
Intrathecal opiates can  gain access both to the substantia gelatinosa in the cord and the respiratory 
and vomiting centre via the CSF. Epidurally administered agents however have two possible routes 
of access to the cord -one via  CSF and the other via axonal transmission.
A comparison of action and efficacy of spinally applied opioid and local anaesthetic agents:
Actions Opioids Local Anaesthetics
a. Site of 
Action
Substantia gelatinosa of 
dorsal horn of spinal 
cord.
Nerve roots (and long tracts 
in spinal cord).
b. Type of 
blockade
Presynaptic and (post 
synaptic) inhibition of 
neuronal cell excitation.
Blockade of nerve impulse 
conduction in axonal 
membrane.
c. Modalities 
blocked
Selective block of pain 
conduction
Blockade of sympathetic 
pain fibres often also loss of 
sensation and motor 
function.
Type of pain and efficacy of blockade
a. Surgical pain Partial relief Complete relief possible
b. Labour pain Partial relief Complete relief
c. Postoperative 
pain early 
first 24 hours
Fair relief (High dose) Complete relief
24 Hours + Good relief (low dose) Complete relief
Chronic pain Good relief Impracticable
GABA Receptor
Midazolam when given  intrathecally  produces  analgesia  by  acting  on  spinal  GABA 
receptors.  There are two types of GABA receptors GABA A  and  GABA B. Midazolam binds 
to the alpha subunit  of  the pentamer GABA A receptor leading to conformational change, 
causing  increased  chloride  ion  conductance  and  hyperpolarisation  and  thereby  acts  by 
potentiating the inhibitory neuro transmitter GABA. This  is  mostly  a  post  synaptic action 
while GABA B receptors mainly have pre synaptic antinociceptive effect by decreasing the 
excitatory neuro transmitter release.
            Intrathecal Midazolam positively modulates GABA A/ Benzodiazepine receptor 
complex  causing  the  release  of  an  edogenous  opioid  acting  at  opioid  receptors  and  also 
intrathecal midazolam causes antinociception, by combining with three different receptor sub 
types of GABA A in the spinal cord9,10.
PHARMACOLOGY
BUPRENORPHINE
Buprenorphine  Hydrochloride  is  a  semi  synthetic  derivative  of  morphine  alkaloid, 
thebaine  and  is   highly  lipophilic  (opioid)  with  a  strong  analgesic   and  marked  narcotic 
antagonist activity. It is 20-50 times more  potent than Morphine. Buprenorphine has molecular 
formula C29 H41 NO4 HC1 with a molecular weight of 5049.
PHARMACOLOGICAL ACTION AND SIDE EFFECTS
Buprenorphine in a single intramuscular dose of 0.3mg relieved pain for up to 6 hours. 
Higher dose (up to 0.6mg) did not provide, significantly greater pain relief. Houde et al 1976 
reported  that  (intramuscular)  Buprenorphine  was  about  28  times  as  potent  as  morphine  in 
analgesic activity.
It produces analgesia by modifying the emotional reaction to pain and by raising the 
pain threshold. It also provides sedation and hypnosis.
NARCOTIC ANTAGONISTIC ACTIVITY
Houde et  al  (1976) proved in  patients  receiving chronic  (about 18 days)  high doses 
(gradually increasing doses up to 8mg intramuscular daily by day 14). Buprenorphine HCL 
treatment, the effect of single dose of 15-20 mg of Morphine were blocked.
The antagonistic activity of Buprenorphine Hcl also has been demonstrated following 
fentanyl (or) Sufentanyl anesthesia, where Buprenorphine has been used to reverse anaesthetic 
effects12.
RESPIRATORY EFFECTS
Respiratory depressant activity of buprenorphine appears to reach a ceiling at a dose of 
about 0.6 to 1.2 mg (im (or) (iv). Respiratory depression is slow in onset (peak effect 3 hours 
after  administration)  and  last  longer  (upto  7  hours)  (Goodman,  Gillman").  The  significant 
decrease  in  minute  volume,  which  (occurred)   1  hour  after  (iv)  0.3  mg was  rapidly  (but 
temporarily) antagonised by IV injection of a single dose of respiratory stimulant doxapram 0.5 
- 1mg/kg (225mg over 2 hours). Very high doses of naloxone produced only partial reversal of 
respiratory depression.
In spontaneously breathing anesthetised patients, intramuscular dose of 3 and 4 mcg/kg 
buprenorphine decreased both the respiratory rate and volume.
CARDIO - VASCULAR EFFECTS
Buprenorphine produced reduction in heart rate (10%) and decrease in  systolic blood 
pressure (5-10%) with only minor decrease in (diastolic) pressure,  central venous pressure, 
cardiac index, stroke index, and left vertricular work decreasing by about 12 to 17%.
DEPENDENCE LIABILITY STUDIES
There are two kinds of dependence associated with drugs acting at narcotic receptors - 
pshycic  and physical.  Buprenorphine hydrochloride  has  a much lower dependence liability 
than morphine.
Withdrawal  symptoms  were  mild  to  moderate  and  they  demanded  drugs  for  relief. 
However, Mello and Mendelson (1980) reported in their experimental subjects no withdrawal 
symptoms upon abrupt withdrawal.
PHARMACOKINETIC STUDIES
Absorption
Well  absorbed  by  most  routes  including  the  sublingual  0.4  to  0.8  mg  and  the 
concentration  in  the  blood  peaks  within  2  hours  and  allows  absorption  directly  into  the 
systemic circulation.
Distribution
Highest levels of radioactivity was found in liver both after oral and (im) injection but 
peak levels in this organ occurred  (10mts) after an oral than after an (im) (40mts) dose. It 
crosses placenta and appears to accumulate in the foetal gastrointestinal lumen.
Protein Binding
The drug is  highly  protein bound (about  96%) primarily  to  alpha and beta  globulin 
fraction.
Metabolism
Buprenorphine hydrochloride is conjugated with glucuronic acid during passage through 
the gut wall. In the bile it is present as glucuronide conjugate of buprenorphine hydrochloride 
as, N-De alkyl Buprenorphine but the CNS contains only unconjugated drug suggesting that the 
effects of buprenorphine are mediated by interaction of the drug alone with opiatereceptors.
Excretion
Excreted mainly in faeces unchanged with smaller amounts appearing in urine (N-de 
alkylated and conjugated metabolites). The preservative free  Bu-Prenorphine available  as 0.3 
mg/ml ampoules was used for this study.
MIDAZOLAM
Midazolam is a water soluble imidazo benzo- diazepine and its unique feature being its 
PH dependent imidazole ring which opens at PH<4, and accounts for its water solubility in 
aqueous solution and rapid metabolism at PH>4, the ring closes leading to an increase in lipid 
solubility.
DOSAGE AND ROUTES OF ADMINISTRATION
Routes
Oral, nasal, intramuscular, intravenous, intrathecal and Epidural.
Dosage
Sedation - 0.05 - 0.1 mg/kg
Premedication - 0.07 - 0.08 mg/kg
Induction - 0.1 - 0.3 mg/kg
Infusion - 2.5mg / kg/ hr
Intrathecal - 0.3 - 2 mg
Epidural - 0.1 - 0.2 mg/kg
Mechanism of pain relief in central Neuraxial blocks
Midazolam causes antinociception by combining with three different receptor subtypes 
of  GABA (A) in the spinal cord. 
Intrathecal  midazolam  positively  modulates  GABA  (A)  /  benzodiazepine  receptor 
complex causing the release of an endogenous opioid acting at opioid receptors.
Central nervous system
Decreases cerebral blood flow, cerebral oxygen requirement and intracranial pressure.
Sedation, hypnosis, anxiolysis
Anterograde amnesia, Anticonvulsant
Respiratory system
Transient  apnoea occurs when administered in doses greater than 0.15 mg/kg and in 
opioid premedicated subjects. Potent respiratory depressant, especially in Chronic Obstructive 
Pulmonary disease (COPD) patients.
Cardio-vascular system
Decrease in peripheral vascular resistance and transient  attenuation of  baro-receptor 
reflexes leading to hypotension and tachycardia is seen. In hypovolemic and elderly patients 
there is increased risk of significant hypotension.
Local effects
No venous irritation and thrombophlebitis.
Pharmacokinetics
It has a PH of 3.5 with pka of 6.15
Protein binding 96-98%
Volume of distribution: 1 - 1.51kg
Clearance: 6-8ml/kg/mt
Elimination half time - 1.4 hr., increased in elderly and obesity.
Metabolised by hepatic micro somal enzyme cytochome. P 450 by hydroxylation to 1.0 
H and 40H  derivatives.
Excreted  in  urine  as  glucuronide  conjugates.  Erythromycin  decreases  its  hepatic 
clearance leading to increased duration of action. <0.02% is excreted unchanged, therefore it is 
not  affected  by  renal  failure.  The  preparation  used  in  this  study  was  preservative  free 
midazolam available as 5mg/ml ampuoles.
Bupivacaine
It is an amide type local anaesthetic, synthesized in Sweden by Ekenstan and colleagues 
in 1957. The Pka is 8.1 with molecular weight of 288 and protein binding of 96% being more 
Cardiotoxic (than lignocaine) because of its avid binding to cardiac muscle. It causes less motor 
blockade  than  (lignocaine).  It  is  4  times  as  potent  as  the  latter  because  of  its  high  lipid 
solubility.8
Mechanism of Action
In its unionized form, it enters the cell and after ionization binds to the interior of the 
sodium channels  causing  sodium channel  blockade  leading  to  inhibition  of  propagation  of 
nerve action potential.
PHARMACODYNAMICS
Central nervous system
It  exerts  biphasic effect  with initial  excitation followed by depression of  the central 
nervous system.
Irritability, restlessness, confusion and convulsion followed by stupor, coma and death.
Cardio-vascular system
It is a potent cardiotoxic agent because of its slow dissociation from the cardiac muscle. 
Hence  it  is  contra-indicated  for  intravenous  regional  analgesia.  It  causes  bradycardia  and 
cardiac arrest following intravenous injection.
Pharmacokinetics
It has a slow onset of action of 15 minutes with prolonged duration of action depending 
on mode of administration. It is bound to acid glycoprotein, metabolised by N-de alkylation to 
its metabolite pipecolyloxylidine that is excreted renally. 16% excreted unchanged renally.
Volume of Distribution - 0.471 kg. The plasma level of Bupivacine following intrathecal 
analgesia is 1-1.4g/ml.
The preparation used for  this  study was 0.5% Bupivacaine (heavy) available as  4ml 
ampoules (Preservative free).
Structural formula
1 Butyl 1-2 piperidyl 1 forma 2-6 xylidine hydrochloride monohydrate C18 H28 N20 HCL 
H20.
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REVIEW OF LITERATURE
Extracted from the POPPY, the opium alkaloid was named morphine after the Greek 
goddess of sleep, Morphina (also the Greek god of dreams, Morphews) in 1803 by Fredrich 
Meisuer.
1.  Synder  (1973) discovered the opiate receptors  in the dorsal  horn of spinal  cord,  the 
lower  medulla  and  the  floor  of  the  fourth  ventricle  and  initiated  the  idea  that 
subarachnoid injection of opiates could provide good analgesia
2.  Huges  et  al  (1975),  the  discovery  of  enkephalins  and  complex  endogenous  opiod 
systems initiated the opiod receptor theory and study of pain mechanisms.
3.  Yakash and Rudy studied the spinal action of morphine in animals, the pain relief was 
attributed to the spinal analgesia caused by direct action of narcotics on specific opiate 
receptors.
4.  Kay B (1978), studied the double blind comparison of the effects of morphine 10 mg IV 
and buprenorphine 0.3 mg IV in the prevention of pain after operation.  The drugs were 
given by the anaesthetist at the end of surgery and the onset and severity of pain were 
assessed by a trained nurse.  He found that with buprenorphine the pain relief was far 
more than twice that of morphine.  The only side effect noticed was drowsiness.  The 
incidence being greater after buprenorphine that after morphine.
5.  Wang et al (1979) reported the first use of intrathecal opiates in man.  They studied 8 
patients  with  intractable  pain due to  cancer  of  genito  urinary  tract  with invasion of 
lumbosacral  plexus.   They injected 1 mg and 0.5 mg of  morphine intrathecally  and 
reported that the duration of pain relief ranged from 12-24 hours.
6.  Cousins MJ and Glynn GJ (1979) reported the evidence of selective action of spinal 
narcotics.  They found that 2 mg of Intrathecal morphine gave a pain relief of 24 hours 
after  surgery.   The  absence  of  changes  in  sensory  motor  and  sympathetic  function 
indicates  that  this  form  of  analgesia  may  have  considerable  advantage  over  other 
methods for the relief of severe chronic and acute pain in man.
7. Budd K. (1981) studied (IV) buprenorphine to produce analgesia in the immediate post 
operative period, the dose being titrated against the response of each patient in order to 
obtain  complete  freedom from pain.   In  50  patients  following  LSCS under  general 
anaesthesia, buprenorphine in the dose range 0.4 – 7.0 mg was found to be a potent, long 
lasting and safe analgesic.  Serial blood gas estimations performed on ten of the patients 
confirmed the clinically observed lack of respiratory depression.
8. Watson  and  co-workers  (1982),  who  found  a  longer  duration  of  analgesia  with 
buprenorphine 0.6 mg that  0.3 mg given IV after surgery.  Analgesia and hormonal 
effects  were  greater  with  the  greater  dose  without  a  parallel  increase  in  respiratory 
depression.
9.  Egan Lanz et al (1984), in their double blind study of post – operative analgesia, 158 
patients  who  were  given  epidural  analgesia  with  mepivacaine  or  bupivacaine  with 
buprenorphine for orthopaedic surgery of lower extremities found that analgesia after 
0.15 mg of Buprenorphine was superior to that  after no injections for 6 hours after 
surgery.  0.3 mg of buprenorphine  was superior both to no injections and to 0.15 mg of 
buprenorphine until 12th hour without any evidence of late respiratory depression.  They 
concluded  that  epidural  administration  of  0.3  mg  of  Buprenorphine  may  be 
recommended  for  post  operative  analgesia  following  orthopaedic  surgery  of  lower 
extremities.
10.  Green DW et al (1985), in a randomized double blind trail comparing morphine and 
buprenorphine and post operative analgesia combined with droperidol was conducted in 
60 patients.  Compared with morphine, taken as the standard analgesic, buprenorphine 
was  shown  to  be  a  satisfactory  analgesic  for  major  surgery  with  no  difference  in 
incidence of unwanted effects.
11.  Wolff J et al (1986), in a double blind controlled study, epidural buprenorphine 0.3 mg 
was compared with 4 mg of epidural morphine for post operative pain relief in the first 
24 hours after major orthopaedic surgery.  Duration of action was 620 minutes with 
buprenorphine with no side effects and 580 minutes with morphine with pruritis and 
urinary retention.
12.  Lipp M et at (1987) in a double blind, randomized study of 29 patients who underwent 
orthopaedic  procedures  with  the  additional  effect  of  intrathecal  buprenorphine  on 
isobaric spinal anaesthesia and post operative analgesia.  The injections were 20 mg 
tetracaine (19 patients) or 20 mg tetracaine plus 0.15 mg buprenorphine (10) patients. 
After buprenorphine patients became aware of pain sensation 13 hours after injection; in 
the control group pain free intervals lasts only 9 hours.  There was no alteration in blood 
pressure and pulse rate was slightly diminished with buprenorphine group.
13.  Capogna et al (1988), studied intrathecal 0.03 mg buprenorphine with bupivacaine 30 
mg for post operative analgesia in the elderly patient showed prolonged analgesia with 
minimal disturbance of consciousness and comfortable breathing.  The only side effects 
were nausea and vomiting in 11 and 14 patients respectively.
14.  Calleno D et al (1989) spinal buprenorphine for post operative analgesia after ceasarian 
section.  Group A (controls n = 15) received hyperbaric bupivacaine; group B and C 
received  the  same  but  with  the  addition  of  0.03  mg  or  0.045  mg  buprenorphine, 
respectively.  Patient receiving higher dose had longer effect of 420 minutes than lower 
dose of 173 minutes analgesia without any increase in side effects.
15.  Sen  M  (1992)  studied  intrathecal  buprenorphine  for  post  operative  analgesia  in 
orthopaedic surgery.  Intrathecally either hyperbaric bupivacaine 1 ml in group A (30 
cases)  or  bupivacaine  1  ml  and buprenorphine 300 micrograms in  combination  was 
given, only  minimal disturbance of consciousness and respiration were observed.  The 
only side effect of buprenorphine group was nausea and vomiting in 10 patients.
16.  Nishimi  et  al  (1994)  studied  the  effect  of  intrathecal  administration  of  opioid  on 
minimum alveolar concentration and postoperative pain relief a comparison of morphine 
and buprenorphine showed:
• Intrathecal  administration  of  0.05  mg  and  0.075  mg  of  buprenorphine  has  shown 
analgesic effect without any side effects.
• With  morphine  0.5  mg  there  was  adequate  post  –  operative  analgesia  with  severe 
pruritus
17.  Lundborg et al (1999), studied Intrathecal pain management for progressive systemic 
sclerosis with long term continuous intrathecal buprenorphine / bupivacaine concluded 
intrathecal infusion of buprenorphine / bupivacaine provided satisfactory long term pain 
relief  in  a  patient  with  PSS  associated  raynauds  phenomenon,  skin  ulceration  and 
intractable ischaemic pain.
18. Batra YK. et.al (1999) conducted a randomized study in 30 patients undergoing knee 
arthroplasty to study the analgesic efficacy of intrathecal Midazolam with Bupivacaine. 
They used 2 mg Midazolam and concluded that addition of Midazolam to Bupivacaine 
intrathecally provided better post operative analgesia without any adverse effects.
19.  M.H.  Kim et.  Al  (2000)  conducted  a  double  blind  study  to  evaluate  post  operative 
analgesic effects of intrathecal Midazolam with Bupivacaine for haemorrhoidectomy in 
45 patients (3 groups – 15 patients in each group) while control group received 1 ml of 
0.5% heavy bupivacaine plus 0.2 ml of 0.9% saline intrathecally.  The other two groups 
received 0.2 ml and 0.4 ml of Midazolam along with 1 ml of 0.5% Bupivacaine heavy 
and concluded that the time for first demand analgesia was significantly greater in the 
study group.
20.  Nishiyama et.al (1999) conducted a study to find out the spinal analgesic interaction 
between Midazolam – benzodiazepine – GABAA  receptor agonist and AP5 N methyl D 
aspartate (NMDA) receptor antagonist were tested for their tail withdrawal response by 
tail flicktest after intrathecal administration.  They concluded that spinally administered 
Midazolam  and  AP5  exhibited  potent  synergistic  analgesia  and  acute  thermal 
nociception in rats.
21.  Valentine.  JM.  et.al  (1996)  conducted  a  randomized  clinical  trial  in  52  patients 
scheduled for caesarian section under spinal anesthesia with (1) Bupivacine heavy 0.5%, 
15mg  +  1.2  ml  0.9%  saline,  (2)  Bupivacaine  0.5% heavy  15mg,  0.2  mg  (0.2  ml) 
diamorphine  +  1  ml  of  0.9% saline  (3)  Bupivacaine  heavy  15mg,  0.2  ml  (0.2  mg) 
diamorphine  and  1  mg  (1ml)  Midazolam.   They  concluded  that  Midazolam  has 
antinociceptive effect at spinal level and their study showed statistically significant but 
clinically marginal effect.
22.  Good child C.S. et.al (1996) conducted experiments in rat and found that antinociception 
by intrathecal Midazolam involves endogenous neurotransmitters acting at spinal cord 
delta opiod receptors.
23.  CS  Goodchild  and  KM  Serrao  (1987)  conducted  a  study  to  find  out  the  possible 
analgesic  effect  of  intrathecal  Midazolam  in  rats  and  concluded  that  intrathecal 
Midazolam causes spinally mediated analgesia by binding to benzodiazepine receptors 
in the spinal cord and did not have a local anaesthetic action.
24.  Murat  Bahar  (1997) conducted a study in  rats  and concluded that  Midazolam when 
injected  intrathecally  it  produces  reversible,  segmental,  spinally  mediated 
antinociception.
25.  Kohnu T. et.al (2000) conducted a study to evaluate the site of action of Midazolam in 
adult rat spinal cord slices and concluded that Midazolam augments both the duration of 
GABA mediated synaptic current and the amplitude of GABA induced current by acting 
on GABA A benzodiazepine receptors in substantia gelatinosa neurons.
26. Indian Journal of Anaesthesia[2005] conducted a double blind study on 53 adult ASA 
grade  I/II  patients  and  concluded  that  intrathecal  combination  of  midazo;am  and 
bupivacaine   provides  longer  duration  of  post  operative  pain  relief  as  compared  to 
bupivacaine alone, without prolonging duration of dermatomal sensory block
MATERIALS AND METHODS
The prospective  clinical  study was  conducted  at  the  Govt.  Stanley  Medical  College 
Hospital,  Chennai-1,  in  75  adult  patients  undergoing  elective  Lower  Limb  Orthopaedic 
Surgery.
The hospital ethical committee approved this study and informed consent was obtained 
from each patient.
Study design
An open, randomised, comparative parallel group design was employed.
Inclusion criteria
ASA 1 & II
AGE 18-65
Orthopaedic procedures of Lower Limbs.
Exclusion criteria
ASA III & IV
Bleeding diathesis
Spinal Deformity
Age <18 years> 65 years
CNS disorder
Local anaesthetic sensitivity
Local Sepsis
Number of patients
75 adults 25 in each group
Group  A  received  3.0ml  of  (15mg)  Bupivacanie  (Preservative  free)  
+0.4 ml of 0.9% normal saline.
Group B received 3.0ml (15 ml) of (Bupivacanie)+ (0.4ml)  0.12mg preservative free 
Buprenorphine
Group C received 3.0ml of (15mg) Bupivacanie + (0.4ml) 2 mg of preservative free 
Midazolam
Pre-operative preparation
The patients were explained about the procedure and informed consent was obtained. 
Tablet diazepam 10 mg given as preoperative night sedation. Patients were made familiar with 
the visual analogue scale (VAS) and were trained to use it adequately. Bupivacaine sensitivity 
was also tested. Informed consent was obtained. Pre operative fasting was 6 hrs for solids, 4 hrs 
for clear liquids. Vital signs were recorded on the day of surgery. No premedication was given 
to any patient on morning of surgery.
Investigations
Urine-Albumin and sugar
Haemoglobin
Bleeding time
Clotting time
Blood urea, sugar
Serum creatinine, Elecholytes
ECG and Xray chest
Anaesthetic procedure
Sub arachnoid block. On arrival at operation threatre, basic monitoring was established 
with ECG, NIBP and pulse oxymeter.
Intravenous line started with 18G iv canula on the left forearm and preloaded with a 
crystalloid 10ml/kg,  prior to sub-arachnoid block. With sterile aspetic  prxecautions,  lumbar 
puncture  was  done  with  23G  quincke  type  spinal  needle,  with  the  patient  in  the  lateral 
decubitus position at L3-L4 space and hyperbaric 0.5% bupivacane (Preservative free) + 0.4 ml 
of 0.9% normal saline in group A and 3.0ml of 0.5% Bupivacane with 0.12mg (0.4ml) of 
preservative free Buprenorphine in Group B and 3.0ml of 0.5% Bupivacaine with 2mg (0.4ml) 
of preservative free midazolam in Group C was deposited.
Following intrathecal injection, the patient was immediately placed in supine Position 
and O2 4L/mt administered to all patients with Hudsons nasal canula.
Assessment of the patient with recording of the Data
The following variables were assessed in the operation theatre and post operative ward
1. Vital parameter like heart rate, respiratory rate, mean arterial pressure and oxygen 
saturation were monitored.
2. Dermatomal  sensory  blockade  to  Pin-prick  was  evaluated-maximum levels  of 
impaired sensation noted.
3. Time of onset of analgesia was noted
4. Duration of sensory and motor blockade recorded
5. Pain  was  evaluated  with visual  analog scale  devised  by  Revill  and  Robinson 
(1976) - VAS 0-100mm
0-20mm - No pain
20-40mm - Mild pain
40-60mm - Moderate pain
60-80mm - Severe pain
80-100mm - Unbearable pain
If the patient is asleep, it is taken as no pain. The time of first demand analgesia was 
noted.
6. Modified bromage scale for the onset of and recovery from motor block. 
0 Free  movement  of  legs  and feet,  with  ability  to  raise 
extended leg.
None
1 Inability  to  raise  extended  leg  and  knee  flexion  is 
decreased but full flexion of feet and ankles is present
Partial 33%
2 Inability to raise leg or flex knees, flexion at ankle and 
feet present
Partial 66%
3 Inability to raise leg, flex knee or ankle (or) move toes Complete 
paralysis
7. Sedation score was noted intra-operatively and post-operatively every 4 hours for 
12 hours.
0 = wide awake
1 = Sleeping comfortably responds to verbal commands
2 = Deep sleep but arousable
3 = Deep sleep, not arousable
After completion of surgery, patient was shifted to recovery room and was observed in 
the recovery room for 2 hours post operatively, after which the patient was shifted to surgical 
post-operative ward.
The following parameters were observed post-operatively:
1. Pain assessment - VAS
2. Sedation
3. Heart Rate
4. Respiratory rate
5. Oxygen saturation
6. Time of first demand analgesia
7. Self voiding time
8. Time of recovery from motor block.
9. Side effects like post-operative nausea and vomiting, allergic manifestations and 
neurological deficit.
OBSERVATION AND RESULTS
Study Material
A total of 25 cases each were randomly allocated to one of the following three groups 
of study viz. Group B – 0.5% Bupivacine (Heavy) with Buprenorphine 0.4 ml (0.12 mg); 
Group C – 0.5% Bupivacine (Heavy) with Midozolam 0.4 ml (2 mg); Group A – control (i.e.)  
0.5% Bupivacine (Heavy) preservative free 3.0 ml. +0.4 ml of 0.9% normal saline.
Table 1: Distribution of age of cases by groups$
Age Gr. B Gr. C Gr. A p-value
No. of cases
Mean
S.D.
Median
Mode
Range
25
46.7
10.03
48
38
26-63
25
46.0
10.39
46
48
26-62
25
45.2
10.59
47
48
22-64
0.88
Stat. Significance
 Gr. B vs. Gr. A
 Gr. C vs. Gr. A
 Gr. B vs. Gr. C
p-value
0.61
0.70
0.80
$ Not statistically significant
The mean distribution of cases by age was observed to be generally not statistically significant 
between Group B and Group C as well as between the groups and control.
Table 2: Distribution of height of cases by groups$
Height Gr. B Gr. C Gr. A p-value
No. of cases
Mean
S.D.
Median
Mode
Range
25
162.9
4.56
162
160
155-176
25
162.8
4.74
162
161
155-176
25
163.3
2.77
163
162
159-170
0.92
Stat. Significance
 Gr. B vs. Gr. A
 Gr. C vs. Gr. A
 Gr. B vs. Gr. C
p-value
0.74
0.69
0.95
$ Not statistically significant
The mean distribution of cases by height was observed to be generally not statistically  
significant between Group B and Group C as well as between the groups and control.
Table 3: Distribution of weight of cases by groups$
Weight Gr. B Gr.C Gr. A p-value
No. of cases
Mean
S.D.
Median
Mode
Range
25
64.1
6.51
63
60
55-80
25
63.4
8.99
65
54
45-82
25
63.2
6.04
62
68
52-76
0.89
Stat. Significance
 Gr. B vs. Gr. A
 Gr. C vs. Gr. A
 Gr. B vs. Gr. C
p-value
0.61
0.93
0.75
$ Not statistically significant
The mean distribution of cases by weight was observed to be generally not statistically  
significant between Group B and Group C as well as between the groups and control.
Table 4: Distribution of cases by groups and four-hourly grade of sedation
Four-hourly 
grade of 
sedation
Gr. B Gr. C Gr. A
No. % No. % No. % p-value
Zero-hour
     0
     1
     2
8
10
7
32.0
40.0
28.0
1
16
8
4.0
64.0
32.0
21
4
0
84.0
16.0
0.0
<0.001*
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
<0.001*
<0.001*
0.03*
Four-hours
     0
     1
     2
0
13
12
0.0
52.0
48.0
4
21
0
16.0
84.0
0.0
25
0
0
100.0
0.0
0.0
<0.001*
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
<0.001*
<0.001*
<0.001*
Eight-hours
     0
     1
     2
4
19
2
16.0
76.0
8.0
23
2
0
92.0
8.0
0.0
25
0
0
100.0
0.0
0.0
<0.001*
Stat. Significance
Gr. B vs. Gr. A
Gr.C vs Gr. A
Gr. B vs Gr. C
p-value
<0.001*
0.15
<0.001*
Twelve-hours
     0
     1
     2
20
5
0
80.0
20.0
0.0
25
0
0
100.0
0.0
0.0
25
0
0
100.0
0.0
0.0
0.005*
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.05*
-
0.05*
The distribution of cases by four-hourly grade of sedation was observed to be 
significantly higher among Group B (p≤0.05) up to 12-hours and Group C (p<0.001) up to 
eight hours than control. The grade of sedation was higher among Group C than Group B 
up to 12th hour (p≤0.03) . These are statistically significant.
Table 5:Mean Distribution of cases by groups and SpO2
SpO2 Gr. B
(n=25)
Gr. C
(n=25)
Gr. A
(n=25) p-value
Pre-OP
Mean
SD
98.4
0.76
98.3
0.69
98.6
0.87
0.54
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.49
0.29
0.70
Intra operative
Mean
SD
98.7
0.84
98.7
0.85
98.2
0.87
0.06
Stat. Significance
Gr.B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.05*
0.05*
0.87
0-hour
Mean
SD
98.6
0.87
98.4
0.77
98.7
0.9
0.61
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.63
0.32
0.61
4-hour
Mean
SD
98.4
0.82
98.6
0.81
98.6
0.82
0.69
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.61
0.73
0.39
8-hour
Mean
SD
98.6
0.65
98.6
1.04
98.4
0.86
0.64
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.36
0.46
-
12-hour
Mean
SD
98.5
0.59
98.2
0.87
98.3
1.02
0.38
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr.A
Gr. B vs Gr. C
p-value
0.31
0.77
0.13
* statistically significant
The mean distribution of cases by four-hourly grade of SpO2 was observed to be generally  
not statistically significant between Group B and Group C, and control Group 
Table 6: Mean Distribution of cases by groups and RR
RR Gr. B
(n=25)
Gr. C
(n=25)
Gr. A
(n=25) p-value
Pre-OP
Mean
SD
16.4
1.04
16.2
0.91
16.6
1.08
0.38
Stat. Significance
Gr. B vs. Gr.A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.43
0.16
0.57
Intra operative
Mean
SD
16.4
0.92
16.6
1.19
17.5
1.26
0.002*
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.001*
0.008*
0.69
0-hour
Mean
SD
16.4
0.91
16.3
0.79
16.2
0.91
0.81
Stat. Significance
Gr. B vs.Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.54
0.74
0.74
4-hour
Mean
SD
16.5
0.96
16.1
0.83
16.6
1.04
0.17
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.78
0.08
0.12
8-hour
Mean
SD
16.6
0.92
16.4
0.86
16.4
0.91
0.66
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.15
0.62
0.35
12-hour
Mean
SD
16.6
0.92
16.4
0.86
16.4
0.91
0.66
Stat. Significance
Gr.B Ivs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.44
-
0.43
* statistically significant
The mean distribution of cases by four-hourly grade of Respiratory Rate (RR)  was 
observed to be generally not statistically significant between Group B and Group C,and 
control Group A
Table 7: Mean Distribution of cases by groups and HR
HR Gr. B
(n=25)
Gr. C
(n=25)
Gr. A
(n=25) p-value
Pre-OP
Mean
SD
81.4
7.98
79.2
7.33
82.4
8.32
0.36
Stat. Significance
Gr. B vs. Gr.A
Gr.C vs Gr. A
Gr. B vs Gr. C
p-value
0.67
0.16
0.32
Intra oprative
Mean
SD
79.0
6.09
78.0
7.70
83.6
8.20
0.02*
Stat. Significance
Gr. B vs. Gr.A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.03*
0.02*
0.61
0-hour
Mean
SD
79.7
7.67
77.4
6.65
81.6
8.21
0.15
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.40
0.05*
0.26
4-hour
Mean
SD
81.5
4.01
78.1
5.40
80.7
7.43
0.10
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.62
0.16
0.02*
8-hour
Mean
SD
81.1
6.00
81.5
6.14
81.7
7.64
0.95
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.76
0.92
0.82
12-hour
Mean
SD
80.4
3.70
83.5
7.14
81.3
6.4
0.18
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.54
0.27
0.06
* statistically significant
The mean distribution of cases by four-hourly grade of Heart Rate (HR)  was observed to be 
generally not statistically significant between Group B and Group C, and control Group A
Table 8: Mean Distribution of cases by groups and MAP
MAP Gr. B
(n=25)
Gr. C
(n=25)
Gr. A
(n=25) p-value
Pre-OP
Mean
SD
79.5
3.38
80.7
4.79
82.6
3.89
0.03*
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. Bvs Gr. C
p-value
0.004*
0.13
0.31
Intra operative
Mean
SD
81.0
4.77
80.2
4.67
80.1
6.31
0.82
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs  Gr. A
Gr. B vs  Gr. C
p-value
0.58
0.92
0.59
0-hour
Mean
SD
81.3
3.82
81.6
5.23
81.5
4.94
0.97
Stat. Significance
Gr. B vs.Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.85
0.96
0.81
4-hour
Mean
SD
79.2
3.27
79.4
4.71
81.7
4.85
0.09
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.04*
0.10
0.84
8-hour
Mean
SD
82.2
3.57
79.8
5.90
81.0
3.61
0.16
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.21
0.39
0.08
12-hour
Mean
SD
81.4
3.29
81.3
5.47
81.2
4.58
0.98
Stat. Significance
Gr. B vs. Gr. A
Gr. C vs Gr. A
Gr. B vs Gr. C
p-value
0.83
0.96
0.90
* statistically significant
The mean distribution of cases by four-hourly MAP values was observed to be generally not 
statistically significant between Group B and Group C and control Group A
Table 9: Distribution of cases by groups and side effects
Co-morbid 
conditions
Gr. B Gr. C Gr. A
No. % No. % No. %
p-value
AR
   Yes
   No
1
24
4.0
96.0
0
25
0.0
100.0
0
25
0.0
100.0
0.36
ND
   Yes
    No
0
25
0.0
100.0
0
25
0.0
100.0
0
25
0.0
100.0
-
PONV
    Yes
    No
3
22
12.0
88.0
2
23
8.0
92.0
2
23
8.0
92.0
0.85
$ not statistically significant
There seems to be no significant difference in the distribution of cases by Respiratory 
Depression, Post Operative Nausea and Vomiting and Neurological Deficit among the 
groups studied.
Table 10: Mean duration (in minutes) of effective analgesia 
of cases by groups
Duration of 
effective analgesia Gr. B Gr. A Gr. A p-value
No. of cases
Mean
25
684.2
25
320.8
25
203.1
S.D.
Median
Mode
Range
59.46
645
720
525-726
45.72
320
340
220-420
28.3
200
210
150-260
<0.001*
Stat. Significance
 Gr. B vs. Gr. A
 Gr. C vs. Gr. A
 Gr. B vs. Gr. C
p-value
<0.001*
<0.001*
<0.001*
* Statistically significant
The mean duration of effective analgesia was significantly higher among Group B(684.2) 
than Group C (320.8; p<0.001) and control (203.1; p<0.001). The difference is statistically  
significant even when all three groups are compared together (p<0.001).
Table 11: Distribution of Mean duration of motor block by groups
Duration of motor 
block Gr. B Gr. C Gr. A p-value
No. of cases
Mean
S.D.
Median
Mode
Range
25
180.6
13.34
180
180
150-210
25
176.8
12.01
180
170
150-196
25
175.7
12.2
180
170
150-190
0.35
Stat. Significance
 Gr. B vs. Gr. A
 Gr. C vs. Gr. A
 Gr. B vs. Gr. C
p-value
0.18
0.74
0.30
$ not statistically significant
The mean distribution of cases by duration of motor block values was observed to be 
generally not statistically significant between Group B and Group C as well as between the 
groups and control.
DISCUSSION
The  study  of  post-operative  pain  relief  in  patients  undergoing  various  orthopaedic 
surgeries with 3.0ml of 0.5% [15mg] Bupivacaine [preservative free] +0.4 ml of 0.9% normal 
saline or 3.0ml of 0.5% Bupivacaine with 0.12mg (0.4 ml) Buprenorphine [preservative free] or 
3.0ml  of  0.5%  Bupivacaine  with  2mg  [0.4ml]  of  midazolam  [preservative  free]  given 
intrathecally.
In this study patient gets post-operative pain relief along with the intra-operative pain 
relief. The administration of suitable analgesics to the patients in pain is often inconvenient. 
Hence neuraxial additives is given along with bupivacaine as a single shot spinal anaesthesia
Sundnes et al13 and bertil lofstrom14 showed the time of onset of analgesia was between 
2.mts -5mts.In our study the time of onset of analgesia was between 2.5-4mts in Groups A ,B 
and C. Our results correlates with studies done by Sundnes et al and Bertil Lofstrom.
The highest level of analgesia was T6 with 3.0ml of 0.5% hyperbaric Bupivacaine in 
study done by Stretting et al in 1982. In our study the highest level of analgesia was T6 in 
Group A, B and C. This result correlates with studies done by Stretting et al.13
Bertil  Lofstrom14 recommended  15mg  of  0.5%  hyperbaric  Bupivacaine  for  lower 
extremity procedures and major hip surgery and the motor blockade[Grade III] duration was 
between 2.5-3hours.In our study the motor blockade[Grade III] of Group A; B and C patients 
was between 2.5-3.5hrs.This result correlates with studies done byBertil Lofstrom.
As per Jon Gjessing et al [1979] when the patient is treated prophylatically the amount 
of drug required is considerably less than that would be required if treatment was delayed until 
pain manifests and becomes intensified.In our study the amount of Buprenorphine required for 
12hours of post-operative pain relief was 0.12mg and midazolam 2mg.
In our study all three groups of patients were comfortable during surgery except  one 
patient  in  control  group  complained  of  pain  but  he  did  not  require  analgesia  within  two 
hours.From the second hour of post-operative period onwards,there was a significant change in 
the VAS reading-the control  group patients showed more than 25mm in VAS scale [study 
group were  still  below 25mm of  the  pain scale.]  Four  patients  required  demand analgesia 
immediately after two hours.Ten patients demanded analgesia after three hours and ten patients 
required analgesia after four hours in control group.
In Group III only one patient demanded analgesia after three hours. Two patients started 
complaining  of  pain  but  demanded  analgesia  after  four  hours  .Fifteen  patients  demanded 
analgesia after five hours, six patients demanded analgesia after six hours. One patient had 
effective analgesia upto seven hours.
In Group B all patients demanded analgesia only after 6 hrs and two patients did not 
demand analgesia upto twelve hours.Average time of demand for analgesia was between ten- 
twelve hours.In Group A Average time of demand for analgesia was between three –four hours 
and in Group C average time of demand analgesia was four –six hours.
Y.K  Batra  et  al15 and  M.H.Kim  et  al16 have  used  preservative  free  midazolam 
intrathecally with bupivacaine to increase the duration of postoperative analgesia in human 
beings.
Serrao et al17 used the dose of 2 mg. of midazolam intrathecally to relieve chronic low 
backpain with good results.
In Group B post-operative pain relief with 0.12mg buprenorphine hydrochloride is upto 
twelve hours 
The duration of  action of  buprenorphine  was 10 -15 hours according to  studies by 
Cousins18 and Glynn et al 1979.According to Sen Lipp.M19-upto thirteen hours analgesia with 
intrathecal  0.15mg buprenorphine achieved.  Our study correlates  with studies done by Sen 
Lipp.M
 The ionger duration of action of buprenorphine is because of unusual receptor kinetics of 
the drug. Buprenorphine forms a very avid drug receptor complex, which tends to persist for 
longer  duration  without  dissociation  [Hambrook  and  Rance  1978].  The  affinity  of 
buprenorphine for opiate receptors is 50 times more than that of morphine.
The special  receptor  kinetics  and high lipid  solubility  also explains  buprenorphine`s 
longer  duration of action compared to other lipid soluble drugs like Fentanyl which produces 
an  intense  sharply  segmental   and  short  lived  analgesia  due  to  rapid  aggress  for  the  cord 
[Bromage]20
Nausea and vomiting is due to the rostral spread of opiod in spinal  fluid to intracerebral 
structures including the vomiting center and chemoreceptor trigger zone.The locus of action is 
thought to be an vascularised area postrema lying specifically in the floor of IV ventricle
The incidence of   post-operative  nausea and vomiting ranged from none to  10% in 
studies done by Lanz et al,Chakraborthy 1984; Sen m 1992.21,22
    Our results show that post-operative nausea and vomiting incidence in  Group A is 4% 
and Group C is 8% and in Group C is 12%.Our results correlates with studies done by Lanz 
etal, Chakraborthy[1984] and Sen M [1992]
However  the  nausea  and vomiting  subsided  without  any  treatment.The  incidence  of 
nausea and vomiting is increased  in post-operative ambulation.Since most of the patients in 
this study are in plaster of paris immobilization and cannot ambulate the incidence of nausea 
and vomiting were low.
The  delayed  respiratory  depression  is  a  known  side  effect  of  buprenorphine.Early 
respiratory depression, within one hour of injection seems to be due to vascular uptake and is 
transient[Bromage PR3] ,but the dangerous variety of delayed respiratory depression is intense 
and prolonged for many hours.
The respiratory depression is due to cephalad migration of opioid in CSF and subsequent 
reaction with opioid receptors located in ventral medulla.According to Harcus   et al23 the drug 
associated respiratory depression is estimated to be less than1%. According to Capogna et al24 
there was no respiratory depression in any of his cases receiving intrathecal bupivacaine with 
buprenorphine. In our study there was not a single case of respiratory depression in Groups A B 
and C. Our results correlates with studies done by Capogna et al.
Water soluble opioids like morphine produce respiratory depression more commonly 
than a lipophilic drug like buprenorphine.
Using sedation score of 0,1,2,3 the patients in Group A B and C  were evaluated. In 
control group only 5 patients had mild sedation upto two hours. In midazolam group [Group C] 
8 patients had a score of 2 and remaining 17 patients  had sedation score of  1 upto one hour. 
Twenty patients had sedation score of 1 from two to four hours, only two patients found to be 
sedated from 4-6 hours in Group C.
In buprenorphine group,7 patients had sedation score of 2 and 10 patients had score of1 
upto 4 hours.12 patients had sedation score of 2and 13 patients had sedation score of 1 from 
4-8hours,19 patients had sedation score of 1 for 8-12hours and only four patient had sedation 
score of one after 12hours.
In  Group A and C there  was no significant  change in  the  self  voiding time[urinary 
retention]. None of the patients complained of urinary retention and needed catheterization.
In Group B two patients had urinary retention and required catheterization [8%]. Gudy 
AR25 [1987] reported urinary retention in 8% of his subjects. Chansoriya KP, Singh BP and 
Chauhan S26 [Intrathecal Buprenorphine for post-operative pain relief 1987]reported urinary 
retention  in  6%  of  their  patients.  Our  results  correlated  with  studies  done  by  Gudy  and 
Chansoriya et al 1987.No long term residual effects was noticed in any patients.
In Group B one patient complained of facial Pruritus. Facial Pruritus may be explained 
by the rapid penetration of the opioid to the superficially placed caudal portion of the nucleus 
of the spinal tract of trigeminal nerve. Also pruritus often subsides like loss of bladder function 
with subsequent doses of opioids presumably due to adaptation to the change in sensation. 
According  to  Cousins  MJ  and  Mather  allergic  reaction  is  found  minimally  with  opioid 
use[1984]. Our study correlates with Cousins MJ and Mather` s studies.18
In  our  study,  the  incidence   of  intra-  operative  complications  like  bradycardia  and 
hypotension in all three groups are comparable and insignificant. According to Chansoriya26 
(1987) Lippin19, 1987 there were no significant changes in pulse rate, BP and respiratory Rate, 
attributable to spinal  Buprenorphine.  There was no significant difference of requirement of 
crystalloids and dose of ephedrine hydrochloride. This results correlates with study done by 
Chansoriya (1987) Lippin, 1987. 
In this study the drug buprenorphine is chosen because it is easily available and highly 
lipophilic hence diffusion of drug from CSF to neuraxis is faster and stay of drug in  CSF is of 
less  duration  and  there  is  less  likelihood  of  rostral  spread  hence  there  was  no  respiratory 
depression. It was decided to compare the post operative analgesia provided by buprenorphine 
with midazolam.
A  number  of  experimental  investigations  were  carried  out  to  study  the  effects  of 
intrathecal midazolam. It was found to produce reversible segmental antinociception without 
any evidence of neurotoxicity in both animals and human beings. (Goodchild et-al27 & Serrao17 
& Murat Bahar28)
Benzodiazepine receptors are present throughout the central nervous system including 
the spinal cord. ( whitwam J.G.29)
Goodchild C.S. demonstrated the administration of exogenous benzodiazepine3 in to the 
subarachnoid space. The drug reached to the benzodiazepine receptors – GABA A receptors in 
laminaII of dorsal horn of spinal cord9.
In this study of post operative pain relief the route of administration of additives was by 
single shot subarachnoid injection. This procedure is commonly done in anaesthetic practice 
and easier when compared to epidural anaesthesia technique.
It has other advantages like rapid procedure, quick onset of analgesia, no need for fluid 
overloading and no appreciable changes in BP. PR and respiratory rate.
In this study none of the patient has exhibited any unwanted serious cardiovascular, 
respiratory and CNS effects which has proved buprenorphine and midazolam as safe & suitable 
agents for relief of post operative pain by intrathecal route. Because the duration of analgesia 
provided by buprenorphine is significantly greater than midazolam it can be a more suitable 
agent for post operative pain relief than midazolam especially when longer duration of post 
operative pain relief is warranted.
SUMMARY
A clinical study was undertaken to evaluate the efficacy, duration of pain relief and to 
know the quality of post-operative analgesia provided by neuraxial additives added to local 
anaesthetic agents.
The  study  was  undertaken  in  75  patients  of  ASA  I  and  II  posted  for  lower  limb 
orthopaedic surgery for post operative pain relief Group-A. 25 patients received only 3.0ml of 
hyperbaric  15mg  (3ml)  preservative  free  bupivacaine  +0.4ml  of  0.9%  normal  saline 
intrathecally.
Group B - 25 patients 3.0ml of 0.5% hyperbaric bupivacaine (Preservative free) +0.12 
mg(0.4ml) of buprenorphine (Preservative free) given intrathecally.
Group C - 25 patients - 3.0ml of 0.5% hyperbaric bupivacaine (Preservative free) + 2mg 
(0.4ml) of Midazolam (Preservative free) given intrathecally.
The onset time of analgesia in all three groups was 2½ - 4 minutes. The highest level of 
analgesia in all three group was upto T6 level.
The motor blockade (Grade III) was upto three hours in these groups. The incidence of 
hypotension, bradycardia and pruitus were very low. The post-operative analgesia was upto 12 
hours  in  Group  B  (S.D.59.46)  and  upto  
6 hours in Group C (S.D.45.72).
None of the patients had any respiratory depression, but few patients had nausea and 
vomiting in the intra and post-operative period which was not severe. Urinary Retention (8%) 
and Pruritus (4%) was reported in a small percentage of patients in Group B.
Spinal buprenorphine is better than spinal midazolam in that it is useful for patients who 
require a longer period of pain relief in the Post-operative period and is not associated with 
significant Cardiovascular, Respiratory (or) Central Nervous system side effects.
Spinal  opiate  analgesia  is  better  than  parenteral  opiates  in  that  a  smaller  dose  is 
sufficient, thereby reducing the side effects and the  patients are not unduly sedated and the 
duration  of  analgesia  is  much  longer  than  the  parenteral  route  thereby  avoiding  repeated 
injections.
Spinal opiates score over spinal local anaesthetics in that there is no motor block which 
is  unwanted  in  post-operative  patients.  The  sympathetic  block  they  produce  may  result  in 
hypotension and importantly the duration of action of spinal opiates is much longer than spinal 
local anaesthetics.
The best drug amongst the spinal opiates is yet to be defined. Most of the studies have 
been done with morphine which is a hydrophilic drug and a liphophilic drug like buprenorphine 
has a definite edge as better concentration are achieved in the spinal cord and very little is left 
in CSF curtailing its rostral spread and depression of vital centers.
The optimal dose for an intrathecal administration is lesser than the doses for epidural 
route.
The  addition  of  buprenorphine  to  the  local  anaesthetic  agent  bupivacine  has  not 
interfered with its action as for as duration of action, level of analgesia, the quality of the motor 
and  sensory  blockade  (or)  incidence  of  intra-operative  complication  like  bradycardia, 
hypotension, nausea, vomiting etc. is considered.
A single intrathecal injection of buprenorphine with bupivacaine has produced not only 
a satisfactory anaesthesia but also a prolonged post operative analgesia upto 12 hours, thereby 
avoiding the repeated im or IV injections and also improving the morale of the patient.
Buprenorphine  0.12mg  (Preservative  free)  with  heavy  bupivacaine  15mg  (0.5%) 
(Preservative free) is safe, cheap and provides good, and prolonged post operative analgesia 
without any significant side effects, compared to other available techniques.  This correlates 
with the studies done by Sen Lipp M (1987).
CONCLUSION
Buprenorphine 0.12mg (0.4 ml preservative free) with hyperbaric 0.5% bupivacaine 15mg 
(preservative free) given by intrathecal route is safe, cheap and provides good and prolonged post-
operative analgesia without any significant side effects when compared to midazolam 2 mg (0.4 ml 
preservative free) with hyperbaric 0.5% bupivacaine 15mg (preservative free) given by intrathecal 
route. So this combination can be used for providing prolonged post-operative analgesia for lower 
limb orthopaedic surgeries.
BIBLIOGRAPHY
1.  Alfred Lee J.,  Atkinson R.S.,  Martret  J.,  et  al,  Lumbar puncture and 
spinal  analgesia  (Intradural  and  Extradural)  Churchill  Livingstone, 
Edinburgh, 5th Edition.
2. Alfred  Lee  J.,  Atkinson  R.S.,  Rushman  G.B.,  et  al,  ‘Synopsis  of 
Anaesthesia” Butterworth, Heinemann Ltd., 1993, 11th Edn.
3. Philip  R.  Bromage,  The  price  of  intraspinal  narcotic  analgesia, 
“Anesthesia and Analgesia”, 1981, 461. (Vol.60) No.7.
4. Aitkenhead A.R. and Smith G (1990).   Text book of Anesthesia.  Post – 
operative pain P.449 – 457.
5. Michael  J  Cousins,  Medical  Intelligence.   Intrathecal  and  epidural 
administration of opioids, Anaesthesiology, 1984, 61, 276-310.
6. Cedric  Prys  Roberts,  Andrew  M.S.  Black  (1996).   Management  of 
postoperative  pain.   International  practice  of  Anesthesia.   P. 
2/140/1-2/140/11.
7. Ray H.d. Amours. Michael Feerante (1997).  Peri operative drugs and 
post – operative pain management.   Anaesthesiology clinics of North 
America.  15 (2) : 251-260.
8. Robert K. Stoelting (1991) Midazolam.  Pharmacology and Physiology 
in anaesthetic practice.  P. 126 – 129.
9. Goodchild CS. GABA receptors and benzodiazepines.  British Journal 
of Anesthesia 1993; 71:127-133.
10. Line. Peng YB., Willis W.D., (1996).  Role of GABA receptor subtypes 
in  inhibition  of  primate  spinothalamic  tract  neurons.   Journal  of 
neurophysiology 75: 109-123.
11. Goodman  and  Gilman’s  pharmacological  basis  of  therapeutics,  6th 
Edition, Hypnotics and Sedatives.  P. 362 – 373.
12. Cowan,  Lewis  J.W.,  Agonist  and  antagonist  properties  of 
buprenorphine,  A  new  anti-nociceptive  agent,  Brit.   Journal 
Pharmacology (1977), 60, 537-545.
13. Sundnes K.O.,  Vaagenes  P.,  Skretting P.  et  al,  Spinal  analgesia  with 
hyperbaric  bupivacaine,  effects  of  volume  of  solution,  Brit.  Journal 
Anaesthesia, 1982, (54), 69.
14. Bertil  Lofstrom  J.  and  Mats  Bengtsson,  Spinal  (intradural)  and 
extradural analgesia, General Anaesthesia, 1987, (91) 1086 – 1092.
15. Batra  Y.K.  et.al.  Addition  of  intrathecal  Midazolam  to  Bupivacanie 
produces better post – operative analgesia without prolonging recovery 
– International Journal of Clinical pharmacology and Therapeutics – Vol 
37 No.10/1999   519 – 523.
16. Kim  K.M.  and  Lee  Y.M.  –  Interthecal  Midazolam  increases  the 
analgesic  effects  of  spinal  blockade  with  Buprevacaine  in  patients 
undergoing  haemorrhoidecory  –  British  Journal  of  Ananthesia  –  Jan 
2001.
17. Serrao et.al(1992) – Intrathecal midazolam for the treatment of chronic 
mechanical  low  back  pain  –  a  controlled  comparison  with  epidural 
steroid in a pilot study – pain 5.12.
18. Cousins J.M. and Mathur L.E., “Intrathecal and epidural administration 
of opioids”, Anesthesiology, 1984, 16, 276.
19. Lipp M., Lanz E., Daublander M., 0.15 mg of Intrathecal buprenorphine 
applied for post – operative analgesia.  A double clinical blind study, 
Anesthesist, 1987, May 36 (5), 233-8.
20. Bromage  P.R.,  Practice  of  spinal  narcotic  analgesia  –  Basic 
Consideration – Anesthesia and Analgesia, 1981, Vol. 60, 461.
21. Egon Lanz. Gabriele Simko, Dieter. T. et al. Extradural buprenorphine - 
A  double  blind  study  of  post-operative  analgesia  and  side  effects. 
Anaesthesia - Analgesia (1984, 63, 593-8).
22. Sen.  M.,  Intrathecal  Buprenorphine  for  post-operative  analgesia  in 
orthopaedic surgery, J. Indian Med. Assoc., Jan 90 (1), 5-6.
23. Harcus A.H., Ward A.E., Smith D.W., Buprenorphine in post operative 
pain result in 7500 patients, Anesthesia 1980, Apr. 35 (4), 382-6.
24. Capogna G., Celleno D. Tagariello D. et al, Intrathecal buprenorphine 
for  post  operative  analgesia  in  the  elderly  patients,  Anesthesia  1988, 
Feb. 43 (2), 128-30.
25. Gudi  A.R.,  Narcotic  analgesic  drug  mixture  of  buprenorphine  with 
xylocaine / bupivacaine by single shot extradural blockade and duration 
of post – operative pain relief, 1987, Vol.27, No.1.
26. Chansoriya K.P. Singh B.P., Chauhan S., Intrathecal buprenorphine for 
post – operative pain relief, Indian Journal Anaesthesia, 1987, 35 (5), 
332.
27. Goodchild  C.S.  Guo  Z.  Musgreave  A.  and  Gent  J.P.  (Dec.  1996)  : 
Antinociception  by  Intrathecal  Midazolam  involves  endogenous 
neurotransmitters  acting  at  Spinal  cord  delta  opioid  receptors  British 
Journal of Anesthesia 77: 758 – 76.3
28. Murat  Bahar  (1997).   Spinal  anesthesia  with  Midazolam  in  the  rat. 
Canadian Journal of Anesthesia  44: 208-215.
29. Whitwam  J.G.  (1983)  Benzodiazepine  receptors  (editorial). 
Anaesthesia, 38, 93-95.
30. Luke M., Kithata and Collins J.G., Spinal Action of Narcotic analgesics 
Anaesthesiology, (1981), 54, 153-163.
31. Alon E, Schulthess. G., Hossli G. et al, “A double blind comparison of 
Tramadol and buprenorphine in the control of post – operative pain”, 
Anesthetist, 1981, 30 (12), 623-6.
32. Budd  K,  High  dose  of  buprenorphine  for  post  operative  analgesia”, 
Anesthesia, 1981 – 36 (9), 900 – 3.
33. Celleno  d,  Capogna  G.,  Spinal  buprenorphine  for  post  –  operative 
analgesia after caesarian section, Acta Anesthesiol Scand, 1989 Apr. 33 
(3), 236-8.
34. Freedman M, A. comparison of buprenorphine and pentazocine for the 
relief of post – operative pain, South African Med. Journal 1986, Jan 
4;69(1) 27-8.
35. Hovell. B.C. “Comprison of Buprenorphine, Pethidine and Pentazocine 
for the relief of pain after operation” British Journal Anaesthesia, 1977, 
49; 913.
36. Mcquay H.J., Bullingham R., Paterson G.M., et al, Clinical effects of 
buprenorphine  during  and  after  operation,  Brit.  Journal  Anaesthesia 
(1980), 52, 1013.
37. Obel D., Hansen L.K., Huttel M.S. et al, buprenorphine supplemented 
anaesthesia influence of dose and duration of analgesia, Brit. Journal of 
Anaesthesia (1985), 57, 271, 274.
38. Yonemura E, Influence of intrathecal morphine and buprenorphine on 
EEG and their analgesic effects, “Masui’, 1990 Apr. 39(4), 478-86.
39. Veering  B.T.,  Burm.  A.,  “Spinal  Anaesthesia  with  hyperbaric 
bupivacaine – Effects of age on neural blockade and pharmacokinetics”, 
British Journal of Anaesthesia, 1988, 60, 187-194.
40. Valentice et. Al (1996) The effect of intrathecal midazolam on post – 
operative pain – European Journal of Anaesthesiology 1996.  No; 13(6) 
589-93.
41. Van Zundert  AAJ,  Grouls  RJE,  Korsten  HHM, Lambert  DH.  Spinal 
anesthesia  volume  or  concentration  –  what  matters?  Regional 
anaesthesia 1996; 21:112-8.
ANNEXURE
PROFORMA
POST-OPERATIVE ANALGESIA
A COMPARATIVE STUDY OF INTRATHECAL
BUPIVACAINE WITH BUPRENORPHINE AND INTRATHECAL 
BUPIVACAINE WITH MIDAZOLAM
NAME :
HOSPITAL No. :
AGE :
SEX :
WEIGHT :
HEIGHT :
ASA STATUS :
DIAGNOSIS :
SURGERY :
DURATION :
PRE-OPERATIVE : CVS MAP RR
RS PULSE SpO2
DOSE :    1. Bupivacaine (0.5%) Heavy 3.0 CC (15 mgs.)
     2. Buprenorphine  (Preservative Free) 0.4 ml (0.12 mg)
     3. Midazolam (Preservative Free) 0.4 ml (2 mg)
POST-OPERATIVE EVALUATION
Variables
Peak
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Op
POST OPERATIVE PERIOD (MINUTES)
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Respiratory 
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from  Motor 
Block
First 
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Time of 
First Self-
voiding
SIDE 
EFFECTS
Nausea
Vomiting
Sedation
Allergic
Reactions
Neurological 
Defecit
